197 related articles for article (PubMed ID: 30580975)
1. Surfactant Administration in Preterm Infants: Drug Development Opportunities.
Taylor G; Jackson W; Hornik CP; Koss A; Mantena S; Homsley K; Gattis B; Kudumu-Clavell M; Clark R; Smith PB; Laughon MM
J Pediatr; 2019 May; 208():163-168. PubMed ID: 30580975
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of surfactant preparations in premature infants.
Trembath A; Hornik CP; Clark R; Smith PB; Daniels J; Laughon M;
J Pediatr; 2013 Oct; 163(4):955-60.e1. PubMed ID: 23769501
[TBL] [Abstract][Full Text] [Related]
3. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome.
Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S
J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.
Jeon GW; Oh M; Sin JB
Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992
[TBL] [Abstract][Full Text] [Related]
5. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.
Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS
Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293
[TBL] [Abstract][Full Text] [Related]
6. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome.
Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U
Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435
[TBL] [Abstract][Full Text] [Related]
7. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.
Fujii A; Allen R; Doros G; O'Brien S
J Perinatol; 2010 Oct; 30(10):671-6. PubMed ID: 20336077
[TBL] [Abstract][Full Text] [Related]
8. Three-year perinatal outcomes of less invasive beractant administration in preterm infants with respiratory distress syndrome.
Ramos-Navarro C; Sánchez-Luna M; Zeballos-Sarrato S; González-Pacheco N
J Matern Fetal Neonatal Med; 2020 Aug; 33(16):2704-2710. PubMed ID: 30526187
[No Abstract] [Full Text] [Related]
9. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.
Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R;
Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381
[TBL] [Abstract][Full Text] [Related]
10. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
[TBL] [Abstract][Full Text] [Related]
11. Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial.
Dargaville PA; Kamlin COF; Orsini F; Wang X; De Paoli AG; Kanmaz Kutman HG; Cetinkaya M; Kornhauser-Cerar L; Derrick M; Özkan H; Hulzebos CV; Schmölzer GM; Aiyappan A; Lemyre B; Kuo S; Rajadurai VS; O'Shea J; Biniwale M; Ramanathan R; Kushnir A; Bader D; Thomas MR; Chakraborty M; Buksh MJ; Bhatia R; Sullivan CL; Shinwell ES; Dyson A; Barker DP; Kugelman A; Donovan TJ; Tauscher MK; Murthy V; Ali SKM; Yossuck P; Clark HW; Soll RF; Carlin JB; Davis PG;
JAMA; 2021 Dec; 326(24):2478-2487. PubMed ID: 34902013
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of late surfactant preparations: a retrospective study.
Lane MD; Kishnani S; Udemadu O; Danquah SE; Treadway RM; Langman A; Balevic S; Jackson WM; Laughon M; Hornik CP; Greenberg RG; Clark RH; Zimmerman KO
J Perinatol; 2021 Nov; 41(11):2639-2644. PubMed ID: 34285358
[TBL] [Abstract][Full Text] [Related]
13. Bovine or Porcine: Does the Type of Surfactant Matter?
Boshoff Coyles L; Joolay Y; Tooke L
J Trop Pediatr; 2020 Oct; 66(5):534-541. PubMed ID: 32112649
[TBL] [Abstract][Full Text] [Related]
14. Neurodevelopmental outcomes of very low birth weight preterm infants treated with poractant alfa versus beractant for respiratory distress syndrome.
Eras Z; Dizdar EA; Kanmaz G; Guzoglu N; Aksoy HT; Altunkaya GB; Canpolat FE; Dilmen U
Am J Perinatol; 2014 Jun; 31(6):463-8. PubMed ID: 23884719
[TBL] [Abstract][Full Text] [Related]
15. Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study.
Paul S; Rao S; Kohan R; McMichael J; French N; Zhang G; Simmer K
J Paediatr Child Health; 2013 Oct; 49(10):839-44. PubMed ID: 23802801
[TBL] [Abstract][Full Text] [Related]
16. Underdosing of Surfactant for Preterm Babies with Respiratory Distress Syndrome in Clinical Practice: A Retrospective Cohort Study.
Boix H; Rite S; Arruza L; Fernandez C; Serrano I; Baquedano I; Sanchez A; Ferreira E; Fernandez P; Gonzalez R; Elorza MD
Am J Perinatol; 2019 Jul; 36(9):943-948. PubMed ID: 30414597
[TBL] [Abstract][Full Text] [Related]
17. Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial.
Lemyre B; Fusch C; Schmölzer GM; Rouvinez Bouali N; Reddy D; Barrowman N; Huneault-Purney N; Lacaze-Masmonteil T
PLoS One; 2017; 12(5):e0175922. PubMed ID: 28472058
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Different Types of Natural Surfactants by Lung Ultrasound in Respiratory Distress Syndrome.
Bozkaya D; Dizdar EA; Korkut S; Ceran B; Alkan M; Oğuz ŞS
Am J Perinatol; 2021 May; 38(6):590-596. PubMed ID: 31770784
[TBL] [Abstract][Full Text] [Related]
19. The influence of the technique of surfactant administration (LISA vs INSURE) on the outcomes of respiratory distress syndrome treatment in preterm infants.
Kaniewska U; Gulczyńska E
Dev Period Med; 2019; 23(3):163-171. PubMed ID: 31654994
[TBL] [Abstract][Full Text] [Related]
20. Impact of Minimally Invasive Surfactant Therapy in Preterm Infants at 29-32 Weeks Gestation.
Dargaville PA; Ali SKM; Jackson HD; Williams C; De Paoli AG
Neonatology; 2018; 113(1):7-14. PubMed ID: 28922658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
